ArticleFrontiers in medicine2025
Delamanid-containing regimens over 24 weeks for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis: preliminary results from a single center in a multicenter, prospective, observational study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04421495 (Safety and Effectiveness of Delamanid-containing Regimen for Treatment of Patients With Multidrug-resistant Tuberculosis in China), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Effectiveness of Delamanid-containing Regimen for Treatment of Patients With Multidrug-resistant Tuberculosis in China
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Single center preliminary results from a multicenter, prospective, observational study whose aims were to investigate the efficacy and safety of 24-week delamanid-containing regimens in Chinese multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) patients. Methods: The study included adult patients (≤65 years old) with laboratory-confirmed MDR/RR-TB who were assigned to receive 24 weeks of delamanid (100 mg, twice daily) plus an optimized background regimen (OBR), followed by 5 ~ 12 months of continuation treatment with OBR alone according to World Health Organization and Chinese guidelines. Results: Thirty-three patients were enrolled, 26 of whom completed the entire treatment course (intensive + continuation phases), with a treatment success rate of 78.8% (95% CI, 61.1, 91.0). Among the 29 patients who were baseline culture-positive, sputum culture conversion was observed in 25 (86.2%) patients within 24 weeks of delamanid treatment, with a median time to sputum culture conversion of 38 days (interquartile range: 24-77). A total of 18 (54.6%) patients experienced treatment-emergent adverse events (TEAEs), most of them being grade 1 or 2 in severity. Six (18.2%) patients had delamanid-related TEAEs, of whom 5 (15.2%) discontinued the delamanid treatment due to QT interval prolongation (2, 6.1%), gastrointestinal reactions (2, 6.1%) or atrial premature beat (1, 3.0%). Conclusion: The preliminary findings of the present single-center study indicated that the 24-week delamanid-containing regimen demonstrated a promising treatment outcome in Chinese MDR/RR-TB patients. A 24-week follow-up period of safety outcomes was basically consistent with the overall results of the multicenter investigation, and close monitoring of QT interval prolongation should in particular be carried out when delamanid is combined with clofazimine and levofloxacin. Clinical trial registration: https://clinicaltrials.gov/study/NCT04421495, identifier NCT04421495.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.